Abstract
The importance of muscarinic synapses in the central nervous system is well-known. Potent toxins such as atropine, known to the ancient Romans, block acetylcholine binding to its receptor. Selective effects of scopolamine on memory have for many years implicated cholinergic mechanisms in learning and memory. A specific hypothesis has been proposed relating lack of acetylcholine at muscarinic synapses with the symptomatology of Alzheimer’s disease (1). In addition, several neurological and psychiatric diseases are associated with apparent loss of cholinergic markers in the brain, or are responsive to treatment with anti-cholinergic agents. The role of the muscarinic synapse in the development and treatment of CNS diseases thus assumes a potentially central role, the understanding of which underlies the possibility of rational treatment. In addition to a possible altered cholinergic neurotransmission in Alzheimer’s disease (1,2), there are indications that changes in muscarinic receptor (mAChR) function may underlie Huntington’s disease (3), depression (4–6), temporal lobe epilepsy (7) and narcolepsy (8). Also, anti-muscarinic agents have been reported to improve symptoms in Parkinson’s disease (9) and dystonia (10,11). Several classes of frequently prescribed medications have significant anti-muscarinic potencies, including various anti-psychotic, antidepressant and anti-histaminergic agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J. T. Coyle, D. L. Price and M. R. DeLong, Alzheimer’s disease: A disorder of cortical cholinergic innervation, Science 219: 1184 (1983).
R. D. Terry and R. Katzman, Senile dementia of the Alzheimer type, Ann. Neurol. 14: 497 (1983).
E. D. Bird and L. L. Iversen, Huntington’s chorea: Post mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia, Brain 97: 457 (1974).
D. S. Janowsky, M. K. El-Yousef, J. M. Davis and H. J. Sekerke, A cholinergic-adrenergic hypothesis of mania and depression, Lancet 11: 6732 (1972).
S. C. Risch, R. M. Cohen, D. S. Janowsky, N. H. Kalin, N. Sitaram, J. C. Gillin and D. L. Murphy, Physostigmine induction of depressive symptomatology in normal human subjects, Psychiatry Res. 4: 89 (1981).
S. C. Dilsaver and J. F. Greden, Antidepressant withdrawal-induced activation (hypomania and mania): Mechanism and theoretical significance, Brain Res. Rev. 7: 29 (1984).
J. G. Fitz and J. O. McNamara, Muscarinic cholinergic regulation of epileptic spiking in kindling, Brain Res. 178: 117 (1979).
R. E. Boehme, T. L. Baker, I. N. Mefford, J. D. Barchas, W. C. Dement and R. D. Ciaranello, Narcolepsy: Cholinergic receptor changes in an animal model, Life Sci. 34: 1825 (1984).
S. Fahn and D. B. Calne, Considerations in the management of parkinsonism, Neurology 28: 5 (1978).
R. E. Burke, S. Fahn, J. Jankovic, C. D. Marsden, A. E. Land, S. Gollomp and J. Ilson, Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs, Neurology 32: 1335 (1982).
S. Fahn, High dosage anticholinergic therapy in dystonia, Neurology 33: 1255 (1983).
M.-M. Mesulam, E. J. Mufson, B. H. Wainer and A. I. Levy, Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Chl-Ch6), Neuroscience 10: 1185 (1983).
K. A. Frey, R. L. E. Ehrenkaufer, S. Beaucage and B. W. Agranoff, Quantitative in vivo receptor binding. I. Theory and application to the muscarinic cholinergic receptor, J. Neurosci. 5: 421 (1985).
K. A. Frey, R. L. E. Ehrenkaufer and B. W. Agranoff, Quantitative in vivo receptor binding. II. Autoradiographic imaging of muscarinic cholinergic receptors, J. Neurosci. 5: 2407 (1985).
K. A. Frey, R. D. Hichwa, R. L. E. Ehrenkaufer and B. W. Agranoff, Quantitative in vivo receptor binding III: Tracer kinetic modeling of muscarinic cholinergic receptor binding, Proc. Natl. Acad. Sci. USA 82: 6711, 1985.
K. A. Frey, R. A. Koeppe, D. M. Jewett, G. K. Mulholland, R. D. Hichwa, D. E. Kuhl and B. W. Agranoff, The in vivo distribution of [11c ‘scopolamine in human brain determined by positron emission tomography, Soc. Neurosci. Abstracts 13: 1658 (1987).
R. A. Koeppe, K. A. Frey, D. E. Kuhl and B. W. Agranoff, Tracer kinetic analysis of [11C]scopolamine binding in human brain, Soc. Neurosci. Abstracts 13: 1658 (1987).
S. K. Fisher and B. W. Agranoff, Receptor activation and inositol lipid hydrolysis in neural tissues, J. Neurochem. 48: 999 (1987).
M. J. Berridge and R. F. Irvine, Inositol trisphosphate, a novel second messenger in cellular signal transduction, Nature 312: 315 (1984).
P. F. Worley, J. M. Baraban, S. Supattapone, V. S. Wilson and S. H. Snyder, Characterization of inositol trisphosphate receptor binding in brain. Regulation by pH and calcium, J. Biol. Chem. 262: 12132 (1987).
R. F. Irvine and R. M. Moor, Microinjection of inositol 1,3,4,5tetrakisphosphate activates sea urchin eggs by a mechanism dependent on external Ca2+, Biochem. J. 240: 917 (1986).
M. G. Low, Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors, Biochem. J. 244: 1 (1987).
H. Woelk, K. Kanig and K. Peiler-Ichikawa, Incorporation of 32P into the phospholipids of neuronal and glial cell enriched fractions isolated from rabbit cerebral cortex, J. Neurochem. 23: 1057 (1974).
A. A. Abdel-Latif, S.-J. Yau and J. P. Smith, Effect of neurotransmitters on phospholipid metabolism in rat cerebral-cortex slices-cellular and subcellular distribution, J. Neurochem. 22: 383 (1974).
R. A. Gonzales, J. B. Feldstein, F. T. Crews and M. K. Raizada, Receptor mediated inositide hydrolysis is a neuronal response: Comparison of primary neuronal and glial cultures, Brain Res. 345: 350 (1985).
B. Pearce, M. Cambray-Deakin, C. Morrow, J. Grimble and S. Murphy, Activation of muscarinic and of al-adrenergic receptors on astrocytes results in the accumulation of inositol phosphates, J. Neurochem. 45: 1534 (1985).
N. M. Cohen, D. M. Schmidt, R. C. McGlennen and W. L. Klein, Receptor-mediated increases in phosphatidylinositol turnover in neuron-like cell lines, J. Neurochem. 40: 547 (1983).
S. K. Fisher and R. M. Snider, Differential receptor occupancy requirements for muscarinic cholinergic stimulation of inositol lipid hydrolysis in brain and in neuroblastomas, Mol. Pharmacol. 32: 81 (1987).
S. B. Masters, T. K. Harden and J. H. Brown, Relationships between phosphoinositide and calcium responses to muscarinic agonists in 1321N1 astrocytoma cells, Mol. Pharmacol. 26: 149 (1984).
S. K. Fisher, C. A. Boast and B. W. Agranoff, The muscarinic stimulation of phospholipid labeling is independent of its cholinergic input. Brain Res. 189: 284 (1980).
S. K. Fisher, K. A. Frey and B. W. Agranoff, Loss of muscarinic receptors and of stimulated phospholipid labeling in ibotenatetreated hippocampus, J. Neurosci. 1: 1407 (1981).
L. E. Hokin, Autoradiographic localization of the acetylcholine-stimulated synthesis of phosphatidylinositol in the superior cervical ganglion, Proc. Natl. Acad. Sci. USA 53: 1369 (1965).
L. E. Hokin, Effects of acetylcholine on the incorporation of 34P into various phospholipids in slices of normal and denervated superior cervical ganglia of the cat, J. Neurochem. 13: 179 (1966).
S. K. Fisher, P. D. Klinger and B. W. Agranoff, Muscarinic agonist binding and phospholipid turnover in brain, J. Biol. Chem. 258: 7358 (1983).
S. K. Fisher, J. C. Figueiredo and R. T. Bartus, Differential stimulation of inositol phospholipid turnover in brain by analogs of oxotremorine, J. Neurochem. 43: 1171 (1984).
R. A. Gonzales and F. T. Crews, Characterization of the cholinergic stimulation of phosphoinositide hydrolysis of rat brain slices, J. Neurosci. 4: 3120 (1984).
M. D. Jacobson, M. Wusteman and C. P. Downes, Muscarinic receptors and hydrolysis of inositol phospholipids in rat cerebral cortex and parotid gland, J. Neurochem. 44: 465 (1985).
D. W. Gil and B. B. Wolfe, Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase, J. Pharmacol. Exp. Ther 232: 608 (1985).
M. C. Olianas, P. Onali, N. H. Neff and E. Costa, Adenylate cyclase activity of synaptic membranes from rat striatum. Inhibition by muscarinic receptor agonists, Mol. Pharmacol. 23: 393 (1983).
J. H. Brown and S. L. Brown, Agonists differentiate muscarinic receptors that inhibit cyclic AMP formation from those that stimulate phosphoinositide metabolism, J. Biol. Chem. 259: 377 (1984).
M. McKinney, S. Stenstrom and E. Richelson, Muscarinic responses and binding in a murine neuroblastoma clone (N1E-115). Mediation of separate responses by high affinity and low affinity agonist-receptor conformations, Mol. Pharmacol. 27: 223 (1985).
S. K. Fisher, Inositol lipids and signal transduction at CNS muscarinic receptors, Trends Pharmacol. Sci. Suppl: Subtypes of Muscarinic Receptors 11: 61 (1986).
T. Evans, J. R. Hepler, S. B. Masters, J. H. Brown and T. K. Harden, Guanine nucleotide regulation of agonist binding to muscarinic cholinergic receptors, Biochem. J. 232: 751 (1985).
S. K. Fisher and R. T. Bartus, Regional differences in the coupling of muscarinic receptors to inositol phospholipid hydrolysis in guinea pig brain, J. Neurochem. 45: 1087 (1985).
R. P. Stephenson, A modification of receptor theory, Br. J. Pharmacol. 11: 379 (1956).
J. H. Brown and D. Goldstein, Differences in muscarinic receptor reserve for inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis in chick heart cell, Mol. Pharmacol. 30: 566 (1986).
T. K. Harden, M. M. Heng and J. H. Brown, Receptor reserve in the calcium-dependent cyclic AMP response of astrocytoma cells to muscarinic receptor stimulation: Demonstration by agonist-induced desensitization receptor inactivation, and phorbol ester treatment, Mol. Pharmacol. 30: 200 (1986).
B. Ringdahl, Determination of dissociation constants and relative efficacies of oxotremorine analogs at muscarinic receptors in the guinea pig ileum by pharmacological procedures, J. Pharmacol. Exp. Ther. 228: 199 (1984).
S. B. Masters, M. T. Quinn and J. H. Brown, Agonist-induced desensitization of muscarinic receptor-mediated calcium efflux without concomitant desensitization of phosphoinositide hydrolysis, Mol. Pharmacol. 27: 325 (1985).
L. G. Costa, G. Kaylor and S. D. Murphy, Carbachol and norepinephrine-stimulated phosphoinositide metabolism in rat brain: Effect of chronic cholinesterase inhibition, J. Pharmacol. Exp. Ther. 239: 32 (1986).
M. Watson, T. W. Vickroy, W. R. Roeske and H. I. Yamamura, Functional and biochemical basis for multiple muscarinic acetylcholine receptors, Prog. Neuropsychopharmacol. Biol. Psychiatry 9: 569 (1985).
T. I. Bonner, N. J. Buckley, A. C. Young and M. R. Brann, Identification of a family of muscarinic acetylcholine receptor genes, Science 237: 527 (1987).
A. M. Heacock, S. K. Fisher and B. W. Agranoff, Enhanced coupling of neonatal muscarinic receptors in rat brain to phosphoinositide turnover, J. Neurochem. 48: 1904 (1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer Science+Business Media New York
About this chapter
Cite this chapter
Agranoff, B.W., Fisher, S.K., Heacock, A.M., Frey, K.A. (1988). The Phosphoinositide-Linked CNS Muscarinic Receptor. In: Kito, S., Segawa, T., Kuriyama, K., Tohyama, M., Olsen, R.W. (eds) Neuroreceptors and Signal Transduction. Advances in Experimental Medicine and Biology, vol 236. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-5971-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-4757-5971-6_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-5973-0
Online ISBN: 978-1-4757-5971-6
eBook Packages: Springer Book Archive